Abstracts Archive - Page 2319 of 2607 - ACR Meeting Abstracts

Abstract Number: 1719 • 2013 ACR/ARHP Annual Meeting
High Reliability Was Found for Ultrasound Scoring of Osteophytes in Patients With Hand Osteoarthritis Using An Atlas As Reference; An Omeract Initiative
Hilde B. Hammer¹, Alexander Mathiessen¹, Annamaria Iagnocco², Emilio Filippucci³, Frédérique Gandjbakhch⁴, Marion C. Kortekaas⁵, Ingrid Möller⁶, Esperanza Naredo⁷, Richard J. Wakefield⁸, Philippe Aegerter⁹ and Maria-Antonietta d'Agostino¹⁰, ¹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Sapienza University of Rome, Rome, Italy, ³Clinica Reumatologica, Università Politecnica delle Marche, Ancona, Italy, ⁴Department of Rheumatology, APHP, Pitié Salpétrière Hospital, Universite Paris 6, Paris, France, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto Poal de Reumatologia, Barcelona, Spain, ⁷Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁸NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁹Epidemiology, Versailles-Saint Quentin en Yvelines University- APHP, Ambroise-Paré Hospital,, Boulogne-Billancourt,, France, ¹⁰Rheumatology, Ambroise Paré Hospital, and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France
Background/Purpose: Ultrasound (US) is a sensitive method for detecting osteophytes (OP) in hand osteoarthritis (HOA). To improve the reliability of scoring OP, an US atlas…
Abstract Number: 1720 • 2013 ACR/ARHP Annual Meeting
Risk Of Cardiovascular Disease and Use Of Xanthine Oxidase Inhibitors For Gout
Seoyoung C. Kim¹, Sebastian Schneeweiss², Niteesh Choudhry³, Jun Liu⁴, Robert J. Glynn³ and Daniel H. Solomon³, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hyperuricemia and gout are associated with an increased risk of hypertension and cardiovascular disease (CVD) such as myocardial infarction (MI) and stroke. Xanthine oxidase…
Abstract Number: 1721 • 2013 ACR/ARHP Annual Meeting
A Prediction Tool for Incident Gout Among Those With Hyperuricemia
Liseth Siemons¹ and Eswar Krishnan², ¹Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ²Medicine, Stanford University, Palo Alto, CA
Background/Purpose: The most common form of inflammatory arthritis observed in men is gout, a condition characterized by hyperuricemia and deposition of uric acid crystals in…
Abstract Number: 1722 • 2013 ACR/ARHP Annual Meeting
Does Starting Allopurinol Prolong Acute Treated Gout?
Erica Hill¹, Jay B. Higgs², Karen Sky³, Michelle Sit⁴ and Angelique N. Collamer⁵, ¹Rheumatology, San Antonio Military Medical Center, Fort Sam Houston, TX, ²Rheumatology, San Antonio Military Medical Center, JBSA - Fort Sam Houston, TX, ³Rheumatology, US Department of Veterans Affairs, Alaska VA Healthcare System, Anchorage, AK, ⁴Subspecialty Clinic - Rheumatology, David Grant Medical Center, Travis AFB, CA, ⁵Internal Medicine, Langley AFB Hospital, Langley AFB, VA
Background/Purpose: Gout is a common cause of morbidity in the US population. Traditionally, allopurinol is not initiated during an acute episode to avoid prolonging…
Abstract Number: 1724 • 2013 ACR/ARHP Annual Meeting
The Role Of Low-Grade Inflammation In The Association Between Uric Acid and Atherosclerosis: The Codam Study
José M.A. Wijnands¹, Annelies Boonen², Pieter C. Dagnelie³, Marleen M.J. van Greevenbroek⁴, Carla J.H, van der Kallen⁵, Isabel Ferreira⁴, Casper G. Schalkwijk⁴, Edith J.M. Feskens⁶, Sjef van der Linden², Coen D.A. Stehouwer⁷ and Ilja C.W. Arts³, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University, Maastricht, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Epidemiology, Maastricht University, Maastricht, Netherlands, ⁴Department of Internal Medicine, Maastricht University, Maastricht, Netherlands, ⁵Department of Internal Medicine, Maastricht University, Maastricht, Netherlands, ⁶Division of Human Nutrition, Wageningen University, Wageningen, Netherlands, ⁷Department of Internal Medicine, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Uric acid may be involved in the atherosclerotic process by increasing the level of low-grade inflammation. The aims of this study were: 1) to…
Abstract Number: 1726 • 2013 ACR/ARHP Annual Meeting
Survivin Inhibition Disturbs Bcl-6 and Blimp-1 Control Of Lymphocyte Maturation and Alleviates Antigen-Induced Arthritis
Mattias Svensson¹, Karin Andersson¹, Malin Erlandsson¹, Ing-Marie Jonsson² and Maria Bokarewa¹, ¹Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Göteborgs University, Göteborg, Sweden
Background/Purpose: Survivin is a proto-oncogene known to regulate cell division and apoptosis. In patients with rheumatoid arthritis, survivin has emerged as an independent predictor of…
Abstract Number: 1727 • 2013 ACR/ARHP Annual Meeting
Novel Selective Inhibitors Of Nuclear Export Attenuate Inflammation and Prevent Bone Mineral Density Loss In Multiple Preclinical Models Of Rheumatoid Arthritis
Mwanasha Hamuza¹, Yosef Landesman¹, Boris Klebanov¹, Michael Kauffman¹, Sharon Shacham¹, Judith Endres², David A. Fox³ and Dilara McCauley¹, ¹Karyopharm Therapeutics Inc., Natick, MA, ²Rheumatology/Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ³Rheumatology/Int Medicine, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Exportin 1 (XPO1; also called chromosome region maintenance 1, CRM1) is a key protein that controls the export of ~220 cargo proteins and several…
Abstract Number: 1688 • 2013 ACR/ARHP Annual Meeting
Does The Treatment With Anti-Coagulants and Anti-Platelets Protect Giant Cell Arteritis Patients From Visual Manifestations?
Andreas P. Diamantopoulos, Helene Hetland, Glenn Haugeberg, Dag Magnar Soldal and Geirmund Myklebust, Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway
Background/Purpose: Visual manifestations such as diplopia, amaurosis fugax or blindness occur in up to half of the giant cell arteritis (GCA) patients. Some studies have…
Abstract Number: 1689 • 2013 ACR/ARHP Annual Meeting
Antiplatelet Agents Decrease Ischemic Complications In Systemic Large Vessel Vasculitides: A Meta-Analysis
James Jeong¹ and Lillian J. Barra², ¹Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada, ²Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: Large Vessel Vasculitides (LVV) consist of Giant Cell Arteritis and Takayasu’s Arteritis, which are chronic systemic autoimmune diseases characterized by inflammation of large blood…
Abstract Number: 1685 • 2013 ACR/ARHP Annual Meeting
Long-Term Use Of Tocilizumab For The Treatment Of Giant Cell Arteritis
Sebastian Unizony¹, John Stone² and Brian Keroack³, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Maine Medical Center, Tufts University Medical School, Maine, ME
Background/Purpose: A sizeable percentage of giant cell arteritis (GCA) patients experience disease relapse upon glucocorticoid (GC) tapering, and a clearly effective GC-sparing alternative has not…
Abstract Number: 1686 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Refractory Takayasu Arteritis: a Case Series and Updated Literature Review.²
Noemie Abisror¹, Arsene Mekinian², Christian Lavigne³, Marie Anne Vandenhende⁴, Michael Soussan⁵ and Olivier Fain¹, ¹Internal Medicine, Jean Verdier Hospital, Bondy, France, ²Internal Medicine, Jean Verdier Hospital, Bondy, FL, France, ³Internal Medicine, Angers, France, ⁴Internal Medicine, Bordeaux, France, ⁵Nuclear Medicine, Avicennes Hospital, Bobigny, France
Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review.Background/Purpose: The aim of this study is to analyze the efficacy and tolerance of…
Abstract Number: 1687 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Refractory Aortitis: A Multicenter Study Of 13 Patients
Javier Loricera¹, Ricardo Blanco², Santos Castañeda³, Alicia Humbría⁴, Sheila Melchor⁵, Jaime Calvo-Alen⁶, Elena Aurrecoechea⁶, Íñigo Rúa-Figueroa⁷, Norberto Ortego⁸, Mauricio Mínguez⁹, Gabriel Herrero-Beaumont¹⁰, Beatriz Bravo¹¹, Jose Rosas¹², Javier Narvaez¹³, Javier Calvo¹⁴, Rafael Ariza¹⁵, Mercedes Freire¹⁶, M. Enriqueta Peiró¹, Vanesa Calvo-Río¹, Francisco Ortiz-Sanjuán² and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, ³Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS-Princesa, Madrid, Madrid, Spain, ⁵Rheumatology, Hospital Universitario 12 de Octubre. Madrid, MADRID, Spain, ⁶Rheumatology, Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ⁷Rheumatology, Hospital Universitario Dr Negrín. Las Palmas, Las Palmas de Gran Canaria, Spain, ⁸Autoimmune Disease Unit, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, ⁹Rheumatology, Hospital Universitario San Juan. Alicante, Alicante, Spain, ¹⁰Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz, Madrid, Spain, ¹¹Pediatric rheumatology, Hospital Virgen de las Nieves. Granada, Granada, Spain, ¹²Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ¹³Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁴Rheumatology, Consorcio Hospital General Universitario. Valencia, Valencia, Spain, ¹⁵Rheumatology, University Hospital Virgen Macarena.Sevilla, Sevilla, Spain, ¹⁶Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain
Background/Purpose: Aortitis can occur alone or associated with other conditions. It is often refractory to standard immunosuppressive therapy. IL-6 has been implicated in the mechanisms…
Abstract Number: 1690 • 2013 ACR/ARHP Annual Meeting
Impaired Vitamin D Receptor Signaling Upregulates Transforming Growth Factor Beta (TGFβ) Signaling In Systemic Sclerosis
Pawel Zerr¹, Stefan Vollath¹, Katrin Palumbo-Zerr¹, Michal Tomcik², Jingang Huang¹, Alfiya Distler¹, Christian Beyer¹, Clara Dees¹, Oliver Distler³, Georg Schett⁴ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Vitamin D receptor (VDR) is a member of the nuclear receptor superfamily. Its ligand, 1,25-(OH)2D, is a metabolically active hormone derived from vitamin D3.…
Abstract Number: 1691 • 2013 ACR/ARHP Annual Meeting
The STAT1 Signaling Pathway In Giant Cell Arteritis
Bjorn Hartmann¹, Joyce Liao², Michael H. Weisman³, Kenneth J. Warrington⁴, Jorg J. Goronzy¹ and Cornelia M. Weyand⁵, ¹Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Byers Eye Institute at Stanford, Stanford University, Palo Alto, CA, ³Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁵Medicine, Stanford University School of Medicine, Stanford, CA
Background/Purpose: In giant cell arteritis (GCA), CD4 T cells, macrophages and multinucleated giant cells form granulomatous lesions in the walls of medium and large arteries.…
Abstract Number: 1692 • 2013 ACR/ARHP Annual Meeting
Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy
Nanguneri R. Nirmala¹, Nico Wulffraat², Hermine Brunner³, Pierre Quartier⁴, Riva Brik⁵, Liza McCann⁶, Huri Ozdogan⁶, Lidia Rutkowska-Sak⁶, Rayfel Schneider^3,7, Valeria Gerloni⁸, Liora Harel⁹, Maria Terreri³, Kristin Houghton³, Rik Joos⁶, Daniel Kingsbury³, Jorge M. Lopez-Benitez³, Arndt Brachat¹⁰, Stephan Bek¹⁰, Martin Schumacher¹⁰, Marie-Anne Valentin¹¹, Hermann Gram¹⁰, Ken Abrams¹², Alberto Martini⁶, Nicolino Ruperto⁶ and Daniel J. Lovell³, ¹Novartis Institutes for Biomedical Research, Cambridge, MA, ²PRINTO, Genoa, Italy, ³Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ⁴Necker-Enfants Malades Hospital, Paris, France, ⁵Pediatrics, Rambam Medical Center, Haifa, Israel, ⁶Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, ⁷Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Canada, ⁸Istituto Gaetano Pini, Milan, Italy, ⁹Pediatric Rheumatology unit, Schneider Children's Medical Center, Tel Aviv University, Petach Tikvah, Israel, ¹⁰Novartis Institutes for Biomedical Research, Basel, Switzerland, ¹¹Biomarker Development, Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Interleukin (IL)-1β plays a key role in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].